Wong Vivien 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Jun 23, 2020
Insider Transaction Report
Form 4
Wong Vivien
Executive Vice President
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−82,500→ 0 totalExercise: $4.52Exp: 2026-02-28→ Common Stock (82,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−75,000→ 0 totalExercise: $4.70Exp: 2024-03-02→ Common Stock (75,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−94,875→ 0 totalExercise: $6.62Exp: 2028-02-29→ Common Stock (94,875 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−40,000→ 0 totalExercise: $9.81Exp: 2022-02-28→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−52,800→ 0 totalExercise: $4.70Exp: 2024-03-02→ Common Stock (52,800 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−82,500→ 0 totalExercise: $11.32Exp: 2027-02-28→ Common Stock (82,500 underlying) - Disposition to Issuer
Common Stock
2020-06-19−4,121→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−6,000→ 0 totalExercise: $5.35Exp: 2020-06-30→ Common Stock (6,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−25,000→ 0 totalExercise: $4.83Exp: 2020-10-31→ Common Stock (25,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−60,000→ 0 totalExercise: $7.40Exp: 2021-06-30→ Common Stock (60,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−48,000→ 0 totalExercise: $5.03Exp: 2023-04-03→ Common Stock (48,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−66,000→ 0 totalExercise: $6.65Exp: 2025-03-01→ Common Stock (66,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−90,750→ 0 totalExercise: $4.52Exp: 2029-03-01→ Common Stock (90,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−82,214→ 0 totalExercise: $4.77Exp: 2030-03-02→ Common Stock (82,214 underlying)
Footnotes (6)
- [F1]On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. Pursuant to the Merger Agreement, each share of Progenics common stock was cancelled and converted into the right to receive (i) 0.31 of a share of Lantheus common stock (with such fraction of a Lantheus share having a market value of $4.60 on the effective date of the Merger) and (ii) one contingent value right (a "CVR") issued by Lantheus subject to and in accordance with the Contingent Value Rights Agreement, dated June 19, 2020, between Lantheus and Computershare Trust Company, N.A.
- [F2]Each of these options is fully vested and exercisable.
- [F3]At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the current vesting and other terms of the option continue in effect.
- [F4]This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2018.
- [F5]This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2019.
- [F6]This option is scheduled to vest in annual installments over the three-year period commencing March 2, 2020.